Biocept, Inc. (BIOC)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.61-0.03 (-2.13%)
As of 11:06 AM EDT. Market open.
People also watch:
SGNLCAPNATOSGBSNGENE
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.60
Prev Close1.64
Bid1.59 x 1000
Ask1.60 x 100
Day's Range1.58 - 1.69
52wk Range1.42 - 7.68
1y Target EstN/A
Market Cap13.48M
P/E Ratio (ttm)-1.74
BetaN/A
Volume18,212
Avg Vol (3m)75,353
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Clinical Results Demonstrating the Performance of Biocept's Target Selector Platform to be Presented at the 2016 European Society of Medical Oncology Annual Congress

    SAN DIEGO, Sept. 29, 2016 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians ...

  • Capital Cube7 days ago

    ETF’s with exposure to Biocept, Inc. : September 23, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Biocept, Inc. Here are 5 ETF’s with the largest exposure to BIOC-US. Comparing the performance and risk of Biocept, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire7 days ago

    Biocept's Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences

    SAN DIEGO, Sept. 23, 2016 /PRNewswire/ -- Biocept, Inc. (BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that Lyle Arnold, Ph.D., Chief Scientific Officer of Biocept, will present at two SelectBio conferences being held between September 26-30 in San Diego.  Dr. Arnold's presentations will focus on Biocept's patented Target-Selector™ technology, which uses liquid biopsy to detect and monitor tumor biomarkers to aid physicians in making treatment decisions for patients with cancer. Biocept, Inc. is a molecular diagnostics company with commercialized assays for lung, breast, gastric, colorectal and prostate cancers, and melanoma.  The Company uses its proprietary liquid biopsy technology to provide physicians with information for treating and monitoring patients diagnosed with cancer. The Company's patented Target Selector™ liquid biopsy technology platform captures and analyzes tumor-associated molecular markers in both CTCs and in plasma (ctDNA). With thousands of tests performed, the platform has demonstrated the ability to identify cancer mutations and alterations to inform physicians about a patient's disease and therapeutic options. For additional information, please visit www.biocept.com.